

The Pituitary Tumour Module: Developing a Condition Specific Module within the European Registries for Rare Endocrine Conditions (EuRRECa)

Ana Luisa Priego Zurita¹, Natasha Appelman-Dijkstra¹, Nienke Biermasz¹, Jillian Bryce¹, Pia Burman³, Luis Castano⁴, Mehul T. Dattani⁵, Olaf M. Dekkers¹, Hoong-Wei Gan⁶, Sonia Gaztambide⁴, Harshini Katugampola⁶, Helene Lasolle⁷, Hermann L. Müller⁸, Gerald Raverot⁷, Itxaso Rica⁴, Charlotte N. van Beuzekom¹, Friso de Vries¹, Amir H. Zamanipoor Najafabadi⁹, S. Faisal Ahmed^{1, 2, 10}, Alberto M. Pereira¹ ¹Department of Medicine, Division of Endocrinology, Leiden University Medical Centre, ²University of Glasgow, UK, ³Department of Endocrinology, Skane University Hospital Malmö, University of Lund, Sweden, ⁴Hospital Universitario Cruces, UPV/EHU, Biocruces Bizkaia, CIBERDEM/CIBERER, Bilbao, Spain, ⁵Genetics & Genomic Medicine Programme, University College London Great Ormond Street Institute of Child Health, London, UK, ⁶Department of Paediatric Endocrinology, Great Ormond Street Hospital for Children, London, United Kingdom, ⁷Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France, ⁸Department of Pediatrics and Pediatric Hematology/Oncology, University Children's Hospital, Klinikum Oldenburg, Germany, ⁹Department of Neurosurgery, Leiden University Of Glasgow, Developmental Endocrinology Research Group, Royal Hospital For Children - Glasgow, UK.

INTRODUCTION

EuRRECa is the affiliated registry of the European Reference Network for Rare Endocrine Conditions (Endo-ERN). It aims to support the needs of the endocrine and bone community by facilitating the collaboration between patients, health care professionals and researchers across Europe and beyond. It consists of two platforms: an electronic reporting tool, e-REC (e-Reporting of Rare Conditions), which collects the number of new cases encountered every month, and the core registry, which collects a set of core data elements and allows the registering of new and existing patients. e-REC has been collecting new cases of endocrine conditions since 2018 and to date. Pituitary adenoma is the most commonly reported condition with over 2400 cases reported so far.

OBJECTIVE

To develop a pituitary tumour module within the EuRRECa core registry. A secondary aim is to detect cases showing aggressive tumour behaviour, including aggressive pituitary tumours and carcinomas.

METHODS

A group of experts from Endo-ERN, ESE, ENEA and ESPE in the field of hypothalamic and pituitary disorders as well as pituitary tumours met remotely on several occasions between December 2020 and June 2021 to develop a consensus on relevant data fields, including aggressive pituitary tumour.

SUPPORTED BY







RESULTS

A total of 65 variables were grouped in 13 questionnaires that collect several aspects of the care of patients across all age span with pituitary tumours. Questions aimed at identifying aggressive tumours were included in the imaging section (Fig. 2). The module has been incorporated into EuRRECa's core registry platform and is available to complete if the diagnosis of any form of pituitary tumour is selected. Details of these domains will also be widely disseminated through EuRRECa's data dictionary.



Patient ID - 537 Date of Birth - 2000-03-01

Pituitary

Senior Clinician < 18 - N/A Senior Clinician ≥ 18 - N/A

Edit Patient Condition

e-REC ID

First Contact with Centre Clinician Responsible for Patient

Date of Condition Onset

Primary Condition

Specific Diagnosis

How Was Diagnosis Reached

Date of Diagnosis

Participation in Detailed Disease Registry

Detailed Disease Registry

Detailed Disease Registry Patient ID

Biobank Sample Available for Research

Biobank Details

Not Assigned 01/03/2021 Pituitary Adenoma - Select -✓ Pituitary adenoma

01/03/2021

Cushing disease Familial isolated pituitary Functioning gonadotropic Functioning pituitary aden Mixed functioning pituitar Non-functioning pituitary Null pituitary adenoma Prolactinoma Silent pituitary adenoma Somatomammotropinoma TSH-secreting pituitary a X-linked acrogigantism Pituitary carcinoma

Fig. 1 - Patient condition information in the Core Registry and Pituitary conditions included in the module.







CONCLUSION

Pituitary tumour is the most reported condition in e-REC. The development of a dedicated registry will provide the clinicians with the opportunity of sharing aspects of the disease and care of their patients with health care professionals and the research community. A working group consisting of experts across the patient age span from several centres across Europe proved to be a successful strategy in reaching consensus rapidly.

for Rare conditions	Core Regi	stry	
denoma adenoma oma adenoma adenoma		र। PET DUSS	
enoma			

				Bone and Wit	gistry for Rare neral condition		ore Regis		
Date of Birth Current Gender Male			e-REC ID Clinician Responsi Patient	Ana Prieg	0		Condition Specific P Diagnosis	ituitary Adenoma ituitary adenoma 021-03-01	
asic disease module	Auxology para	meters	Endocrine	manifestations	Secreted h	ormones	Visual impairment	Imaging	Genetics
Aedical therapy S	urgical therapy	Radiation	therapy	Medical therapy	outcomes	Surgical	therapy outcomes	Radiation thera	apy outcomes
Tumour behavio	our assessed	d by pos	t-treatm	ent imaging					
Assessment Date			9	dd-mm-jjjj	i				
Assessment Date Age at Assessment	Date		2	dd-mm-jjj	j				
Age at Assessment Has the maximal tu	mour diameter			dd-mm-jjj - Select -					
Age at Assessment Has the maximal tu assessed by post-tr	mour diameter	ng							
	mour diameter eatment imagir ume assessed t	-							







Per ession


www.eurreca.net

eurreca





The project '777215 / EuRRECa' which have received funding from the European Union's Health Programme (2014-2020) and is part of the project '946831 / EuRR-Bone' which has received funding from the European Union's Health Programme (2020-2023).



29ESPE